AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18805509 — intervention group
Group type: COMPARATOR
Intervention: Three times daily (TID) call schedule
Number of subjects: 71
Study 17144555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment including physical factors (ultrasound, sinusoidal modulated currents‐‐SMC) and medicinal suppositories (diklofenak, vitaprost, polyoxidonium)
Number of subjects: 112
Study 17144555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 112
Study 17144555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of physical factors and medicinal suppositories
Number of subjects: 112
Study 14520685 — intervention group
Group type: EXPERIMENTAL
Intervention: Narapril (Julphar, UAE)
Number of subjects: 24
Study 14520685 — intervention group
Group type: COMPARATOR
Intervention: Renitec (MSD, Netherlands)
Number of subjects: 24
Study 11147908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine administration
Number of subjects: 65
Study 11147908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 8790517 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of a standard, photocopied letter signed by the non-attender's doctor with the second invitation to attend for breast screening.
Number of subjects: 465
Study 8790517 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation from the breast screening centre (Control group).
Number of subjects: 465
Study 3056255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 67
Study 3056255 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-tobramycin
Number of subjects: 67
Study 3056255 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 67
Study 3056255 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 67
Study 31306290 — intervention group
Group type: EXPERIMENTAL
Intervention: Johns Hopkins RAPID‐PFA model
Number of subjects: 119
Study 31306290 — intervention group
Group type: COMPARATOR
Intervention: Group conversation condition
Number of subjects: 119
Study 28472933 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rescripting (ImRs)
Number of subjects: 142
Study 28472933 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitisation and reprocessing (EMDR)
Number of subjects: 142
Study 25947010 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient training (n=13)
Number of subjects: 21
Study 25947010 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=8)
Number of subjects: 21
Study 23435496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-same face pairings (two male faces or two female faces)
Number of subjects: 0
Study 23435496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-different face pairings (a male face preceded or followed by a female face)
Number of subjects: 0
Study 21243371 — intervention group
Group type: EXPERIMENTAL
Intervention: Octopus 3°/second
Number of subjects: 40
Study 21243371 — intervention group
Group type: EXPERIMENTAL
Intervention: Octopus 10°/second
Number of subjects: 40
Study 21243371 — intervention group
Group type: COMPARATOR
Intervention: Goldmann
Number of subjects: 40
Study 21243371 — intervention group
Group type: COMPARATOR
Intervention: Octopus 3°/second vs Goldmann
Number of subjects: 40
Study 21243371 — intervention group
Group type: COMPARATOR
Intervention: Octopus 10°/second vs Goldmann
Number of subjects: 40
Study 21243371 — intervention group
Group type: COMPARATOR
Intervention: Octopus 3°/second vs Goldmann (patient group)
Number of subjects: 40
Study 19411798 — intervention group
Group type: EXPERIMENTAL
Intervention: RLG (rocuronium 0.6 mg/kg mixed with 2 mL of 2% lidocaine)
Number of subjects: 75
Study 19411798 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG (rocuronium 0.6 mg/kg with 8.4% sodium bicarbonate)
Number of subjects: 75
Study 19411798 — intervention group
Group type: COMPARATOR
Intervention: RG (rocuronium 0.6 mg/kg)
Number of subjects: 75
Study 17493669 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT+RHPPL (vincristine-cisplatin chemotherapy every 10 days for 3 cycles before RHPPL)
Number of subjects: 288
Study 17493669 — intervention group
Group type: COMPARATOR
Intervention: RHPPL only
Number of subjects: 288
Study 17493669 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT+RHPPL
Number of subjects: 288
Study 15339409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu Granule plus radiotherapy
Number of subjects: 63
Study 15339409 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 63
Study 11840766 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated live hepatitis A vaccine (H2 strain) - 10(6.5) TCID50/ml
Number of subjects: 37000
Study 11840766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37000
Study 10052106 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with uterine fibromatosis
Number of subjects: 31
Study 10052106 — intervention group
Group type: COMPARATOR
Intervention: Women without pathology (control group)
Number of subjects: 31
Study 7474005 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair or resection and anastomosis
Number of subjects: 71
Study 7474005 — intervention group
Group type: COMPARATOR
Intervention: Diversion
Number of subjects: 71
Study 7474005 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair with resection of colon
Number of subjects: 71
Study 7474005 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair or resection with anastomosis
Number of subjects: 71
Study 2147844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% thymoxamine
Number of subjects: 74
Study 2147844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 2147844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% thymoxamine (light irides)
Number of subjects: 74
Study 2147844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% thymoxamine (dark irides)
Number of subjects: 74
Study 7356821 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic filmed programmed instruction
Number of subjects: 14
Study 7356821 — intervention group
Group type: COMPARATOR
Intervention: Control group (slides, bibliotherapy, nonprogrammed activity)
Number of subjects: 14
Study 30910634 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated tablets
Number of subjects: 84
Study 30910634 — intervention group
Group type: COMPARATOR
Intervention: Uncoated tablet
Number of subjects: 84
Study 28362327 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest bathing
Number of subjects: 2
Study 28362327 — intervention group
Group type: COMPARATOR
Intervention: Urban control area
Number of subjects: 2
Study 26293505 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (EX) for 6 months
Number of subjects: 101
Study 26293505 — intervention group
Group type: COMPARATOR
Intervention: Health education control (CON)
Number of subjects: 101
Study 26293505 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (EX)
Number of subjects: 101
Study 24070104 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy for Primary Care (PST‐PC), delivered in 8 weekly telephone sessions of 30-45 minutes duration and 4 monthly maintenance sessions.
Number of subjects: 0
Study 24070104 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral to general practitioner for assessment and treatment)
Number of subjects: 0
Study 20978640 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (SEA) applied on dentin
Number of subjects: 70
Study 20978640 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (SEA) applied on water contaminated dentin
Number of subjects: 70
Study 20978640 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive (SEA) applied on saliva contaminated dentin
Number of subjects: 70
Study 20978640 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyalkenoic acid conditioning
Number of subjects: 70
Study 20978640 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment
Number of subjects: 70
Study 18991972 — intervention group
Group type: EXPERIMENTAL
Intervention: STM touch with ISIO4 blended oil for 10 days
Number of subjects: 49
Study 18991972 — intervention group
Group type: EXPERIMENTAL
Intervention: STM touch with sweet almond oil for 10 days
Number of subjects: 49
Study 18991972 — intervention group
Group type: EXPERIMENTAL
Intervention: All STM groups (almond oil, ISIO4 oil)
Number of subjects: 49
Study 18991972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study 16777920 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc carnosine (ZnC) 37.5 mg twice daily
Number of subjects: 10
Study 16777920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15623266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (physicians receiving education on PIM prescribing)
Number of subjects: 355
Study 15623266 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care physicians)
Number of subjects: 355
Study 11794219 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent split‐virus influenza vaccine
Number of subjects: 2032
Study 11794219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2032
Study 9424902 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterostomy (ZZJ)
Number of subjects: 170
Study 9424902 — intervention group
Group type: EXPERIMENTAL
Intervention: Billroth II method (BII)
Number of subjects: 170
Study 9424902 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncal vagotomy with pyloroplasty (VP)
Number of subjects: 170
Study 9424902 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (WWW)
Number of subjects: 170
Study 9424902 — intervention group
Group type: EXPERIMENTAL
Intervention: Rydygier method (BI-R)
Number of subjects: 170
Study 7819733 — intervention group
Group type: EXPERIMENTAL
Intervention: Presoaked porcine collagen shields with 0.1% betamethasone disodium phosphate and 0.5% netilmycin (group 1)
Number of subjects: 50
Study 7819733 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival injection of 1 mg betamethasone disodium phosphate and 250 mg piperacillin (group 2)
Number of subjects: 50
Study 7819733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1 and 2)
Number of subjects: 50
Study 7819733 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen shields
Number of subjects: 50
Study 3337463 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (4 mg three times daily for 3 days)
Number of subjects: 5
Study 3337463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31873050 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1149
Study 31873050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1149
Study 29701119 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training (n=12)
Number of subjects: 26
Study 29701119 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=14)
Number of subjects: 26
Study 28857042 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 440
Study 28857042 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioural Therapy (CBT)
Number of subjects: 440
Study 26307337 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific laryngeal manipulation (SLM)
Number of subjects: 12
Study 26307337 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural manual therapy (PMT)
Number of subjects: 12
Study 26307337 — intervention group
Group type: COMPARATOR
Intervention: Control (neither SLM nor PMT)
Number of subjects: 12
Study 23879752 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (600 mg loading dose followed by 75 mg/day, with open-label aspirin 50-325 mg/day, recommended 162 mg for 5 days then 81 mg daily)
Number of subjects: 0
Study 23879752 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (50-325 mg/day, with a recommended dose of 162 mg for 5 days then 81 mg daily)
Number of subjects: 0
Study 23879752 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 0
Study 23879752 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 20953211 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNFR-Fc 12.5, 25, 37.5, or 50 mg SC injection (healthy volunteers)
Number of subjects: 52
Study 20953211 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNFR-Fc 25 mg BIW or 50 mg QW (patients with AS)
Number of subjects: 52
Study 20953211 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNFR-Fc (multiple dosages)
Number of subjects: 52
Study 18853110 — intervention group
Group type: EXPERIMENTAL
Intervention: Kushenin 0.6 g once a day
Number of subjects: 55
Study 16649350 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg) for 3 months
Number of subjects: 200
Study 16649350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 14662554 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 453
Study 14662554 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (3-15 mg/d)
Number of subjects: 453
Study 11253478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks (linguistic and visuospatial)
Number of subjects: 16
Study 11253478 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 16
Study 8769301 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU IFN three times a week for six months
Number of subjects: 45
Study 8769301 — intervention group
Group type: COMPARATOR
Intervention: 5 MU IFN daily until HCV-RNA was undetectable in plasma X 3 over 3 consecutive monthly determinations followed by demonstrated HCV-RNA negativity in liver biopsy tissue
Number of subjects: 45
Study 1570963 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline injection
Number of subjects: 260
Study 1570963 — intervention group
Group type: COMPARATOR
Intervention: Normal saline containing 10 U per 1 mL heparin
Number of subjects: 260
Study 6099649 — intervention group
Group type: EXPERIMENTAL
Intervention: Towne live, attenuated cytomegalovirus (CMV) vaccine
Number of subjects: 53
Study 6099649 — intervention group
Group type: COMPARATOR
Intervention: Seropositive kidney transplant
Number of subjects: 53
Study 30478937 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-Logic closed-loop system
Number of subjects: 48
Study 30478937 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 48
Study 30337083 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically relevant respiratory model predicting peak inspiratory pressure after changes to PEEP.
Number of subjects: 4
Study 26851768 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 2 mA tPCS stimulation
Number of subjects: 30
Study 26851768 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 25200403 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg daily for 8 weeks
Number of subjects: 209
Study 22085206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation participation
Number of subjects: 104
Study 22085206 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical experience (Control)
Number of subjects: 104
Study 19268343 — intervention group
Group type: COMPARATOR
Intervention: Sending right pelvic nodes in a single container
Number of subjects: 104
Study 19268343 — intervention group
Group type: COMPARATOR
Intervention: Sending left pelvic nodes in a single container
Number of subjects: 104
Study 19268343 — intervention group
Group type: EXPERIMENTAL
Intervention: Sending pelvic nodes in four containers
Number of subjects: 104
Study 16815741 — intervention group
Group type: EXPERIMENTAL
Intervention: POEM system (Web-based patient-oriented diabetic education management)
Number of subjects: 274
Study 16815741 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard education)
Number of subjects: 274
Study 16411341 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai regimen (zidovudine 300 mg po bid from 36 weeks until labour, zidovudine 300 mg po q3h during labour; neonates received placebo)
Number of subjects: 222
Study 16411341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Short regimen (placebo from 36 weeks to labour, zidovudine 300 mg po q3h in labour; neonates received zidovudine 2 mg/kg po qid for the first three days)
Number of subjects: 222
Study 11673297 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacovitrectomy surgery without prone posture
Number of subjects: 20
Study 11673297 — intervention group
Group type: COMPARATOR
Intervention: Phacovitrectomy with gas tamponade and face down posturing (historical control)
Number of subjects: 20
Study 9640061 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for tick-borne encephalitis (exact treatment details not provided)
Number of subjects: 0
Study 9640061 — intervention group
Group type: COMPARATOR
Intervention: Control group (exact details not provided)
Number of subjects: 0
Study 9640061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial meningitis group (exact details not provided)
Number of subjects: 0
Study 9640061 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of cytokines in CSF
Number of subjects: 0
Study 7734459 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting (CC)
Number of subjects: 360
Study 7734459 — intervention group
Group type: COMPARATOR
Intervention: No contingencies (NC)
Number of subjects: 360
Study 7734459 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication only/CC
Number of subjects: 360
Study 7734459 — intervention group
Group type: COMPARATOR
Intervention: Medication only/NC
Number of subjects: 360
Study 2466359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxendolone 200 mg weekly
Number of subjects: 60
Study 2466359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31659986 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 210
Study 31659986 — intervention group
Group type: COMPARATOR
Intervention: Stent treatment (bare metal stents (BMS) or drug-eluting stents (DES))
Number of subjects: 210
Study 31659986 — intervention group
Group type: COMPARATOR
Intervention: Stent treatment (BMS or DES)
Number of subjects: 210
Study 29158012 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ+SAM (10mg olanzapine + 5mg samidorphan)
Number of subjects: 106
Study 29158012 — intervention group
Group type: COMPARATOR
Intervention: OLZ alone (10mg olanzapine)
Number of subjects: 106
Study 29158012 — intervention group
Group type: COMPARATOR
Intervention: SAM alone (5mg samidorphan)
Number of subjects: 106
Study 29158012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 26968718 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral Buckling (SB)
Number of subjects: 211
Study 26968718 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy without band
Number of subjects: 211
Study 26968718 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with encircling band (EB)
Number of subjects: 211
Study 26968718 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide (TA) assisted vitrectomy
Number of subjects: 211
Study 24631792 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (55-65 minutes of exercise at 4-5 times a week)
Number of subjects: 50
Study 24631792 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (45-55 minutes of exercise at 2-3 times a week)
Number of subjects: 50
Study 24631792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity)
Number of subjects: 50
Study 22623389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish intake (two 150-g salmon portions/wk)
Number of subjects: 123
Study 22623389 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet low in oily fish)
Number of subjects: 123
Study 21092748 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 1220
Study 21092748 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injectable (RIS‐LAI)
Number of subjects: 1220
Study 18160258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically acidified formula with probiotics (Bifidobacterium lactis)
Number of subjects: 132
Study 18160258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically acidified formula without probiotics
Number of subjects: 132
Study 18160258 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically acidified formula
Number of subjects: 132
Study 18160258 — intervention group
Group type: COMPARATOR
Intervention: Standard whey formula
Number of subjects: 132
Study 16730011 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline wound irrigation
Number of subjects: 206
Study 16730011 — intervention group
Group type: COMPARATOR
Intervention: No saline wound irrigation (Control)
Number of subjects: 206
Study 12881375 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular mammography screening
Number of subjects: 0
Study 10918536 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent access to sedentary activities based on 750 pedometer counts
Number of subjects: 34
Study 10918536 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent access to sedentary activities based on 1500 pedometer counts
Number of subjects: 34
Study 10918536 — intervention group
Group type: COMPARATOR
Intervention: Control group (noncontingent access to sedentary behaviors)
Number of subjects: 34
Study 8875083 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 324
Study 8875083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 1561466 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sustained-release isosorbide 5-mononitrate (5-IMN)
Number of subjects: 10
Study 1561466 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of 50 mg of sustained-release isosorbide 5-mononitrate (5-IMN) for 3 weeks
Number of subjects: 10
Study 3893693 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 16
Study 3893693 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 16
Study 3893693 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and Doxorubicin
Number of subjects: 16